Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASK120067 versus gefitinib as first-line treatment for EGFR-mutant advanced non-small cell lung cancer
CTR20191523Phase 3Active
- Sponsor
- Aosaikang Biotherapeutics
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of limertinib, gefitinib in non-small cell lung cancer (NSCLC), Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Aosaikang Biotherapeutics. Started Nov 2019; status: active.
02
Drugs
limertinibgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on CTR20191523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191523.